← boardnext 2026-12
ENTA
Enanta Pharmaceuticals, Incdistress 5/10 · elevated risk$12.82-2%today-24% from 52w high
Infectious Disease 4
Lead: RSV Infection
Revenue
$36M
Liquidity
$98M
Runway
5.1 yrs
Shares 1y
+36%
Price & events
+0.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.8%
1D
-2.8%
1W
-8.8%
1M
-4.0%
3M
-1.5%
6M
+65.8%
1Y
-14.5%
2Y
-69.5%
5Y
-69.5%
All
Overview
- Market Cap
- $372.78M
- Volume
- 7.40K
- 52 Week Range
- $6.49 – $16.85
- Total Shares
- 29.08M
- Float Shares
- 20.06M
- Short %
- 10.64%
- % Held by Insiders
- 4.68%
- % Held by Institutions
- 92.74%
- RVOL
- 0.03x
- Beta
- 0.97
Pipeline stages · 3 programs
zelicapavir
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
EDP-938
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), moxifloxacin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | zelicapavirfast track | RSV Infection, RSV, Respiratory Syncytial Virus (RSV) | — | not yet recruiting |
| 2025-06-23 | Phase 2 | EDP-938 | RSV Infection | 186 | completed |
| 2025-06-06 | Phase 1 | EDP-323, Midazolam, Caffeine | RSV Infection, Drug Drug Interaction | 24 | completed |
| 2025-05-24 | Phase 1 | EDP-323, Itraconazole, carbamazepine | RSV Infection, Drug Drug Interaction (DDI) | 48 | completed |
| 2025-02-02 | Phase 1 | zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), moxifloxacin | RSV Infection, QTc Interval | 72 | completed |
Catalyst news & presentations · 7
- 2027Guided 40%readoutPhase 2zelicapavir · Topline Phase 2b data from registrational trial expected in 2027SEC 8-K
- 4Q 2026Guided 70%trial initiationsecondaryPhase 2/3zelicapavir · Initiation of registrational Phase 2b/3 trial in high-risk adults with RSVSEC 8-K
- 3Q 2026Guided 70%trial initiationsecondaryPhase 2zelicapavir · Initiation of Phase 2b trial in pediatric patients with RSVSEC 8-K
- 2026-08-10Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-23withdrawalPaxlovid · Federal Circuit affirmed that claims of U.S. Patent No. 11,358,953 are invalid.SEC 8-K
- May 11, 2026readoutPaxlovid · Oral argument in patent infringement appealSEC 8-K
- September 29, 2025readoutPhase 2zelicapavir · announced positive topline data from Phase 2b studySEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $21 (+65% upside) · 6 analysts
- 2026-06-23HC Wainwright & Co.Buy
- 2026-02-10HC Wainwright & Co.Buy
- 2026-01-09HC Wainwright & Co.Buy
- 2025-11-14JP MorganOverweight
- 2025-09-30WestPark CapitalBuy
- 2025-09-15Evercore ISI GroupOutperform
Competitors — RSV Infection
- PFEPFIZER INC$142.2B · D3
Recent news
- 2026-07-17Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – BX:9EP - TradingView
- 2026-07-15Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
- 2026-07-14(ENTA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
- 2026-07-07Enanta Pharmaceuticals outlines its antiviral pipeline as investors weigh long-term prospects - Ad-hoc-news.de
- 2026-07-06Enanta Pharmaceuticals (ENTA) Q2 2026 Earnings: Narrower Loss Surprises Amid Steady Pipeline Progress - Financial Health Score - dars.gov.et
- 2026-07-03Enanta Pharmaceuticals outlines its antiviral pipeline. Focus on long-term opportunities for ENTA st - Ad Hoc News
- 2026-07-03Enanta Pharmaceuticals (ENTA) Rebounds 2.3% as Shares Approach Key Resistance Zone - Unusual Call Volume - dars.gov.et
- 2026-07-02Liquidity Mapping Around (ENTA) Price Events - Stock Traders Daily
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.